Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study. 1993

J F Money-Kyrle, and F Bates, and J Ready, and B G Gazzard, and R H Phillips, and F C Boag
Kobler Centre, St Stephen's Clinic, London, UK.

We report a non-randomized Phase II clinical trial to assess the efficacy and safety of liposomal daunorubicin (DaunoXome) in the treatment of AIDS related Kaposi's sarcoma. Eleven homosexual men with advanced Kaposi's sarcoma were entered in the trial. Changes in size, colour and associated oedema of selected 'target' lesions were measured. Clinical, biochemical and haematological toxicities were assessed. Ten subjects were evaluated. A partial response was achieved in four, of whom two subsequently relapsed. Stabilization of Kaposi's sarcoma occurred in the remaining six, maintained until the end of the trial period in four. The drug was generally well tolerated, with few mild symptoms of toxicity. The main problem encountered was haematological toxicity, with three subjects experiencing severe neutropenia (neutrophil count < 0.5 x 10(9)/l). There was no evidence of cardiotoxicity. In this small patient sample, liposomal daunorubicin was an effective and well tolerated agent in the treatment of Kaposi's sarcoma.

UI MeSH Term Description Entries
D008081 Liposomes Artificial, single or multilaminar vesicles (made from lecithins or other lipids) that are used for the delivery of a variety of biological molecules or molecular complexes to cells, for example, drug delivery and gene transfer. They are also used to study membranes and membrane proteins. Niosomes,Transferosomes,Ultradeformable Liposomes,Liposomes, Ultra-deformable,Liposome,Liposome, Ultra-deformable,Liposome, Ultradeformable,Liposomes, Ultra deformable,Liposomes, Ultradeformable,Niosome,Transferosome,Ultra-deformable Liposome,Ultra-deformable Liposomes,Ultradeformable Liposome
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009503 Neutropenia A decrease in the number of NEUTROPHILS found in the blood. Neutropenias
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D003630 Daunorubicin A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS. Daunomycin,Rubidomycin,Rubomycin,Cerubidine,Dauno-Rubidomycine,Daunoblastin,Daunoblastine,Daunorubicin Hydrochloride,NSC-82151,Dauno Rubidomycine,Hydrochloride, Daunorubicin,NSC 82151,NSC82151
D004337 Drug Carriers Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers. Drug Carrier
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

J F Money-Kyrle, and F Bates, and J Ready, and B G Gazzard, and R H Phillips, and F C Boag
June 1996, AIDS (London, England),
J F Money-Kyrle, and F Bates, and J Ready, and B G Gazzard, and R H Phillips, and F C Boag
January 2006, Sarcoma,
J F Money-Kyrle, and F Bates, and J Ready, and B G Gazzard, and R H Phillips, and F C Boag
October 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
J F Money-Kyrle, and F Bates, and J Ready, and B G Gazzard, and R H Phillips, and F C Boag
January 2007, International journal of nanomedicine,
J F Money-Kyrle, and F Bates, and J Ready, and B G Gazzard, and R H Phillips, and F C Boag
May 1993, Lancet (London, England),
J F Money-Kyrle, and F Bates, and J Ready, and B G Gazzard, and R H Phillips, and F C Boag
April 1998, Prescrire international,
J F Money-Kyrle, and F Bates, and J Ready, and B G Gazzard, and R H Phillips, and F C Boag
July 1996, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
J F Money-Kyrle, and F Bates, and J Ready, and B G Gazzard, and R H Phillips, and F C Boag
June 1996, Oncology (Williston Park, N.Y.),
J F Money-Kyrle, and F Bates, and J Ready, and B G Gazzard, and R H Phillips, and F C Boag
September 1997, AIDS (London, England),
J F Money-Kyrle, and F Bates, and J Ready, and B G Gazzard, and R H Phillips, and F C Boag
December 1998, Australian and New Zealand journal of medicine,
Copied contents to your clipboard!